Korean J Ophthalmol.  2019 Aug;33(4):392-394. 10.3341/kjo.2018.0115.

Central Serous Chorioretinopathy Following Intravitreal Dexamethasone Implant

• Noh GM
• Nam KY
• Lee SU
• Lee SJ

• KMID: 2454783
• DOI: http://doi.org/10.3341/kjo.2018.0115

Abstract

No abstract available.

MeSH Terms

Central Serous Chorioretinopathy*
Dexamethasone*
Dexamethasone

Figure

• 

  Fig. 1 Optical coherence tomography of both eyes 3 months after Ozurdex injection, (A–D) revealing subretinal fluid adjacent to the pigment epithelial detachment. (E,F) Fluorescein angiography and (G,H) indocyanine green angiography images revealing late ink blot and smoke stack leakage temporal to the fovea of respective eyes, indicated with arrows. These findings are characteristic of central serous chorioretinopathy. There was no indication of a choroidal neovascular network or polypoidal lesion.

Reference

1. Singer MA, Dugel PU, Fine HF, et al. Real-world assessment of dexamethasone intravitreal implant in DME: findings of the prospective, multicenter REINFORCE study. Ophthalmic Surg Lasers Imaging Retina. 2018; 49:425–435.

2. Eris E, Erdogan G, Perente I, et al. A new side effect of intravitreal dexamethasone implant (Ozurdex). Case Rep Ophthalmol Med. 2017; 2017:6369085.

3. Georgalas I, Petrou P, Pagoulatos D, et al. Central serous chorioretinopathy in the fellow eye as a complication of intravitreal dexamethasone implant for the treatment of Irvine-Gass syndrome. Clin Exp Optom. 2016; 99:601–603.

4. Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011; 52:80–86.

5. Han JM, Hwang JM, Kim JS, et al. Changes in choroidal thickness after systemic administration of high-dose corticosteroids: a pilot study. Invest Ophthalmol Vis Sci. 2014; 55:440–445.